View Clause Headings                                                                                                                                               HelpHelp
DOCUMENT TITLE:  COLLABORATION AND LICENSE AGREEMENT .
ACTIONS: Here are the clause headings in the document. To view the clause, click the clause heading.To view the full document, click the "View Document" button.

View Document Back
Clause Heading
2.1.1 - Establishment
2.1.2 - Responsibilities
2.1.3 - Membership
2.1.4 - Meetings
2.1.5 - Decision Making
2.2.1 - General
2.2.2 - Project Teams
2.3 - Information Sharing
2.4.1 - General
2.4.2 - Minimization of Substitutability
2.4.3 - Japan
3.1 - General
3.2.1 - Acne
3.2.2 - Impetigo
3.3 - During the Continuation Period
3.4 - Diligence
3.5.1 - General
3.5.2 - First Negotiation
3.5.3 - PPOC Notice
3.5.4 - Preset Terms
3.5.5 - Inability to Agree on Terms
3.5.6 - Failure to Respond
3.5.7 - Excluded Indications
3.5.8 - Conflicts
3.5.9 - Expenses
3.6.1 - Establishment
3.6.2 - Contents
3.7 - Disclosure of Formulation Technology
3.8 - Subcontractors
4.1 - Commercialization
4.2 - Commercialization Plan
4.3.1 - General
4.3.2 - Conditions
4.4 - NovaBays Right to Co-promote to Healthcare Institutions in North America
4.4.1 - Co-Promote
4.4.2 - Exercise
4.5 - Cooperation and Consultation
4.6 - Galderma First Right of Negotiation
5.1.1 - Japan Election Notice
5.1.2 - Pre-Pivotal Development
5.1.3 - Pre-Pivotal Japan Report
5.1.4 - Pivotal Trials
5.2.1 - Both Parties Fund
5.2.2 - One Party Funds
5.2.3 - Royalties to Galderma on Japan Sales
6.1.1 - Collaboration Compounds
6.1.2 - Collaboration Products
6.1.3 - Supply by Galderma
6.1.4 - Transfer Price
6.1.5 - Supply Agreement
6.1.6 - Coordination
6.2.1 - Filings
6.2.2 - Clinical Safety Reporting; Pharmacovigilance
6.2.3 - Cooperation
6.2.4 - Regulatory Inspection/Audit Rights
6.3 - Transfer of Data and Regulatory Filings
7.2 - No Other Rights
7.3 - Use of NovaBay Technology
7.4 - Use of Galderma Technology
7.1.1 - To Galderma
7.1.2 - To NovaBay
7.1.3 - No Other Active Ingredients
7.5 - Conflicts of Interest
7.6.1 - Exclusivity
7.6.2 - Discussions
8.1 - Certain Fees
8.1.1 - Upfront Fee
8.1.2 - Monthly Fee
8.1.3 - Completion of Formulation Feasibility Studies
8.2 - Continuation
8.2.1 - Continuation Fee
8.2.2 - Certain Reimbursements
8.3.1 - FTE Funding
8.3.2 - Non-FTE Costs
8.4 - Development Milestone Payments
8.4.1 - Certain Terms
8.4.2 - Milestone Payment Timing
8.5 - Royalty Payments to NovaBay
8.5.1 - Acne Products
8.5.2 - Anti-Bacterial Products
8.5.3 - Anti-Fungal Products
8.5.4 - Anti-Viral Products
8.5.5 - Other Products
8.5.6 - Certain Terms
8.5.7 - Sales Supported by NovaBay
8.5.8 - Certain Royalty Conditions
8.6.2 - Royalty-Bearing NovaBay Products
8.5.9 - Term of NovaBay Royalties
8.6 - Royalty Payments to Galderma
8.6.1 - For Collaboration Products in Japan
8.7 - Material Adverse Events
8.8 - Royalty Reports
8.9 - Payment Method
8.10 - Taxes
8.11 - Records
8.12 - Inspection of Records
8.13 - Late Payment
8.14 - Currency Conversion
9.1.1 - General
9.1.2 - Compound Improvements
9.1.3 - Agreements with Affiliates and Third Parties
9.2.1 - General
9.2.2 - Projected Patent Filings
9.2.3 - NovaBay Patents
9.2.4 - Galderma Patents
9.2.5 - Joint Patents
9.2.6 - Prosecution and Maintenance
9.3 - Defense of Third Party Infringement Claims
9.4 - Enforcement
9.4.1 - Initiating Enforcement Actions
9.4.2 - Recoveries
9.5.1 - By NovaBay after the Effective Date
9.5.2 - By Galderma after the Effective Date
9.5.3 - Other Conditions.
9.6 - Patent Marking
9.7.1 - Galderma Product Marks
9.7.2 - NovaBay Product Marks
9.7.5 - World-wide Branding Strategies
9.7.3 - NovaBay Logo
9.7.4 - Co-Promotion
10.1 - Confidentiality; Exceptions
10.2 - Authorized Use and Disclosure
10.3 - Publications
10.4.1 - Confidential Terms
10.4.2 - Publicity Review
10.5 - Prior Agreements
11.1 - General Representations and Warranties
11.2 - NovaBays Warranties
11.3 - Covenant
11.4 - Disclaimer of Warranties
11.5.1 - Indemnification by NovaBay.
11.5.2 - Indemnification by Galderma
11.5.3 - Procedure
11.6 - Insurance
12.1 - Term
12.2 - Termination by Galderma
12.2.1 - Failure of Formulation Feasibility
12.2.2 - Prior to Continuation Period
12.2.3 - During the Continuation Period
12.2.4 - For Safety Reasons
12.2.5 - Competitive Change of Control .
12.3.1 - General
12.4 - Termination for Failure to Pay the Continuation Fee
12.5.1 - Accrued Obligations
12.5.2 - Non-Exclusive Remedy
12.5.3 - No Milestone Payment
12.5.4 - Return of Materials
12.5.5 - General Survival
12.6 - Effects of Certain Terminations
12.6.1 - Transition Assistance
12.6.2 - Ongoing Trials
12.6.3 - Commercialization
12.6.4 - Regulatory Filings/Data
12.6.5 - Technology Licenses
12.6.6 - Trademarks
12.6.7 - Marketing Partners
12.6.8 - Governance
12.6.9 - Suspension of Activities
12.7 - Termination With Respect to Collaboration Products
12.8.1 - Termination of Certain Provisions
12.8.3 - Field
12.8.4 - In-Process Collaboration Products
12.8.5 - Data
12.10 - Termination Press Releases
13.1 - Dispute Resolution
13.2 - Pre-Arbitration Dispute Resolution
13.3 - Arbitration
13.3.1 - Arbitrator
13.3.2 - Substantive Law
13.3.3 - Enforcement/Service
13.3.4 - Confidentiality of Proceedings
13.3.5 - Costs
13.4 - Provisional Remedies
14.1 - Governing Law
14.2 - Assignment
14.3 - Notices
14.4 - Waiver
14.5 - Severability
14.6 - Entire Agreement/Modification
14.7 - Relationship of the Parties
14.8 - Force Majeure
14.9 - Compliance with Laws
14.10 - Counterparts